Efficacy and Safety of Paliperidone Palmitate 6-Month versus Paliperidone Palmitate 3-Month Long-Acting Injectable in European Patients with Schizophrenia: A Post Hoc Analysis of a Global Phase-3 Double-Blind Randomized Non-Inferiority Study-Reference-Cited by-同舟云学术

Efficacy and Safety of Paliperidone Palmitate 6-Month versus Paliperidone Palmitate 3-Month Long-Acting Injectable in European Patients with Schizophrenia: A Post Hoc Analysis of a Global Phase-3 Double-Blind Randomized Non-Inferiority Study

Published:2023-04 Issue: Volume:Volume 19 Page:895-906
ISSN:1178-2021
Container-title:Neuropsychiatric Disease and Treatment
language:en
Short-container-title:NDT

Author:

Giron‐Hernandez Cesar,Han Joong Hee,Alberio Roberta,Singh Arun^ORCID,García-Portilla Maria Paz,Pompili Maurizio^ORCID,Knight R Karl,Richarz Ute,Gopal Srihari^ORCID,Antunes José^ORCID

Publisher

Informa UK Limited

Reference24 articles.

1. Comparative Effectiveness of Antipsychotic Drugs for Rehospitalization in Schizophrenia—A Nationwide Study With 20-Year Follow-up

2. Clinical Characteristics of Patients With Schizophrenia Who Successfully Discontinued Antipsychotics

3. Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients With Schizophrenia: A Meta-analysis of Prospective and Retrospective Cohort Studies

4. Oral and long‐acting antipsychotics for relapse prevention in schizophrenia‐spectrum disorders: a network meta‐analysis of 92 randomized trials including 22,645 participants

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical effectiveness of paliperidone palmitate 3‐monthly and 1‐monthly as monotherapy in patients with schizophrenia: A retrospective cohort study based on the Medicaid claims database;Neuropsychopharmacology Reports;2024-09-11

2. Treatment patterns and hospitalizations following rejection, reversal, or payment of the initial once-monthly paliperidone palmitate long-acting injectable antipsychotic claim among patients with schizophrenia or schizoaffective disorder;Journal of Managed Care & Specialty Pharmacy;2024-09

3. Three-Year Outcomes of 6-Month Paliperidone Palmitate in Adults With Schizophrenia;JAMA Network Open;2024-07-17

4. Evaluating the 6-month formulation of paliperidone palmitate: a twice-yearly injectable treatment for schizophrenia in adults;Expert Review of Neurotherapeutics;2024-03-06

5. Solid-Liquid Phase Equilibrium of Paliperidone in 15 Kinds of Pure Solvents;2024